

PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 55692

Title: Transarterial chemoembolization with hepatic arterial infusion chemotherapy plus S-1 for hepatocellular carcinoma

Reviewer's code: 05085789

Position: Peer Reviewer

Academic degree: MD, PhD

Professional title: Senior Lecturer

Reviewer's Country/Territory: Japan

Author's Country/Territory: China

Manuscript submission date: 2020-03-29

Reviewer chosen by: AI Technique

Reviewer accepted review: 2020-03-31 04:20

Reviewer performed review: 2020-03-31 10:53

Review time: 6 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

SPECIFIC COMMENTS TO AUTHORS

Comments to the author In the manuscript entitled “Transarterial chemoembolization with hepatic arterial infusion chemotherapy plus S-1 for hepatocellular carcinoma”, the authors demonstrated that TACE combined with HAIC was an effective and safe treatment for patients with advanced HCC with portal vein invasion or extrahepatic metastasis. Furthermore, they also demonstrated no additional effect of S-1 on TACE/HAIC treatment, even though there were similar frequencies of adverse events. While the result of this clinical study was negative, the study design was excellent and manuscript was quite well written. To make the article more persuasive and fruitful, the authors need to discuss the following issue. 1) Patients with advanced HCC characterized by vascular invasions, localized irradiation (especially targeting an invaded portal lesion) would be an alternative treatment. What did authors think about irradiation therapy and how did they decide the treatment for patient with advanced HCC including vascular invasion?